Functional changes of the basal ganglia circuitry in Parkinson's disease

Progress in Neurobiology

Volumn 62, Issue 1, 2000, Pages 63-88

  Blandini, Fabio ^a   Nappi, Giuseppe ^a   Tassorelli, Cristina ^a   Martignoni, Emilia ^a  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 7 CHLOROKYNURENIC ACID; DECAHYDRO 6 PHOSPHONOMETHYL 3 ISOQUINOLINECARBOXYLIC ACID; DIZOCILPINE; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; LEVODOPA; REMACEMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; BASAL GANGLION; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; GLOBUS PALLIDUS; HEREDITY; HUMAN; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS;

ANIMALS; BASAL GANGLIA; BRAIN; CEREBRAL CORTEX; HUMANS; NERVE DEGENERATION; PARKINSON DISEASE;

EID: 0034287012     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-0082(99)00067-2     Document Type: Review

References (230)

1. Agid Y. Levodopa: is toxicity a myth? Neurology. 50:1998;858-863.
2. Ahlskog J.E., Uitti R.J., Low P.A., Tyce G.M., O'Brien J.F., Nickander K.K. Levodopa and deprenyl treatment effects on peripheral indices of oxidant stress in Parkinson's disease. Neurology. 46:1996;796-801.
3. Albers D.S., Weiss S.W., Iadarola M.J., Standaert D.G. Immunohistochemical localization of N-methyl-D-aspartate and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor subunits in the substantia nigra pars compacta of the rat. Neuroscience. 89:1999;209-220.
4. Albin R.L., Greenamyre J.T. Alternative excitotoxic hypotheses. Neurology. 42:1992;733-738.
5. Albin R.L., Makowiec R.L., Hollingsworth Z.R., Dure L.S., Penney J.B., Young A.B. Excitatory amino acid binding sites in the basal ganglia of the rat: a quantitative autoradiographic study. Neuroscience. 46:1992;35-48.
6. Albin R.L., Young A.B., Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12:1989;366-375.
7. Albin R.L., Young A.B., Penney J.B. The functional anatomy of disorders of the basal ganglia. Trends Neurosci. 18:1995;63-64.
8. Alexander G.E., Crutcher M.E. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 13:1990;266-271.
9. Allen K.L., Almeida A., Bates T.E., Clark J.B. Changes of respiratory chain activity in mitochondrial and synaptosomal fractions isolated from the gerbil brain after graded ischaemia. J. Neurochem. 64:1995;2222-2229.
10. Anglade P., Vyas S., Javoy-Agid F., Herrero M.T., Michel P.P., Marquez J., Mouatt-Prigent A., Ruberg M., Hirsch E.C., Agid Y. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. Histopathol. 12:1997;25-31.
11. Aston-Jones G., Shipley M.T., Grzanna R. The locus coeruleus, A5 and A7 noradrenergic cell groups. Paxinos G. The Rat Nervous System. 1995;183-213 Academic Press, San Diego.
12. Aziz T.Z., Peggs D., Sambrook M.A., Crossman A.R. Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropiridine (MPTP)-induced parkinsonism in the primate. Mov. Disord. 6:1991;288-292.
13. Baker D.M., Santer R.M. Development of a quantitative histochemical method for determination of succinate dehydrogenase activity in autonomic neurons and its application to the study of aging in the autonomic nervous system. J. Histochem. Cytochem. 38:1990;525-531.
14. Beal M.F., Hyman B.T., Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci. 16:1993;125-131.
15. Beckstead R.M. Complementary mosaic distributions of thalamic and nigral axons in the caudate nucleus of the cat: double anterograde labeling combining autoradiography and wheat germ-HRP histochemistry. Brain Res. 335:1985;153-159.
16. Berendse H.W., Groenewegen H.J. Organization of the thalamocortical projections in the rat, with special emphasis on the ventral striatum. J. Comp. Neurol. 299:1990;187-228.
17. Bergman H., Wichmann T., DeLong M.R. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science. 249:1990;1436-1438.
18. Bergman H., Wichmann T., Karmon B., DeLong M.R. The primate subthalamic nucleus. Part II: Neuronal activity in the MPTP model of parkinsonism. J. Neurophysiol. 72:1994;507-520.
19. Bernard V., Bolam J.P. Subcellular and subsynaptic distribution of the NR1 subunit of the NMDA receptor in the neostriatum and globus pallidus of the rat: co-localization at synapses with the GluR2/3 subunit of the AMPA receptor. Eur. J. Neurosci. 10:1998;3721-3736.
20. Betarbet R., Turner R., Chocklan V., DeLong M.R., Allers K.A., Walters J., Levey A.I., Greenamyre J.T. Dopaminergic neurons intrinsic to the primate striatum. J. Neurosci. 17:1997;6761-6788.
21. Bettler B., Mulle C. Review: neurotransmitter receptors II. AMPA and kainate receptors. Neuropharmacology. 34:1995;123-139.
22. Bezard E., Gross C.E. Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach. Progr. Neurobiol. 55:1998;93-116.
23. Bezard E., Bourad T., Bioulac B., Gross C.E. Presymtpomatic revelation of experimental parkinsonism. Neuroreport. 8:1997;435-438.
24. Bezard E., Bourad T., Bioulac B., Gross C.E. Compensatory effects of glutamatergic inputs to the substantia nigra pars compacta in experimental parkinsonism. Neuroscience. 81:1997;399-404.
25. Bezard E., Bourad T., Bioulac B., Gross C.E. Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms. Eur. J. Neurosci. 11:1999;2167-2170.
26. Blandini F., Greenamyre J.T. Effect of subthalamic nucleus lesion on mitochondrial enzyme activity in rat basal ganglia. Brain Res. 669:1995;59-66.
27. 3H]dihydrorotenone binding to complex I in intact human platelets. Anal. Biochem. 230:1995;16-19.
28. Blandini F., Porter R.H.P., Greenamyre J.T. Autoradiographic study of mitochondrial complex I and glutamate receptors in the basal ganglia of rats after unilateral subthalamic lesion. Neurosci. Lett. 186:1995;99-102.
29. Blandini F., Porter R.H.P., Greenamyre J.T. Glutamate and Parkinson's disease. Mol. Neurobiol. 12:1996;1-17.
30. Blandini F., Garcia-Osuna M., Greenamyre J.T. Subthalamic ablation reverses changes in basal ganglia oxidative metabolism and motor response to apomorphine induced by nigrostriatal lesion in rats. Eur. J. Neurosci. 9:1997;1407-1413.
31. Blandini F., Conti G., Martignoni E., Colangelo V., Nappi G., Di Grezia R., Orzi F. Modifications of local cerebral metabolic rates for glucose and motor behavior in rats with unilateral lesion of the subthalamic nucleus. J. Cereb. Blood Flow Metab. 19:1999;149-154.
32. Bonuccelli U., Del Dotto P., Piccini P., Behge F., Corsini G.U., Muratorio A. Dextrometorphan on parkinsonism. Lancet. 340:1992;53.
33. 125I ]iodosulpiride. Neuroscience. 20:1987;117-155.
34. Brotchie J.M., Mitchell I.J., Sambrook M.A., Crossman A.R. Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate. Mov. Disord. 6:1991;133-138.
35. Burbaud P., Gross C., Benazzouz A., Coussemacq M., Bioulac B. Reduction of apomorphine-induced rotational behaviour by subthalamic lesion in 6-OHDA lesioned rats is associated with a normalization of firing rate and discharge pattern of pars reticulata neurons. Exp. Brain Res. 105:1995;48-58.
36. Calabresi P., Mercuri N.B., Sancessario G., Bernardi G. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain. 116:1993;433-452.
37. Calabresi P., Pisani A., Centonze D., Bernardi G. Synaptic plasticity and physiological interactions between dopamine and glutamate in the striatum. Neurosci. Biobehav. Rev. 21:1997;519-523.
38. Canteras N.S., Shammah-Lagnado S.J., Silva B.A., Ricardo J.A. Afferent connections of the subthalamic nucleus: a combined retrograde and anterograde horseradish peroxidase study in the rat. Brain Res. 513:1990;43-59.
39. Carter D.A., Fibiger H.C. The projections of the entopeduncular nucleus and globus pallidus in rat as demonstrated by autoradiography and horseradish peroxidase histochemistry. J. Comp. Neurol. 177:1978;113-124.
40. Cepeda C., Levine M.S. Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum. Dev. Neurosci. 20:1998;1-18.
41. Cesura A.M., Ritter A., Picotti G.B., Da Prada M. Uptake, release, and subcellular localization of 1-methyl-4-phenylpiridinium in blood platelets. J. Neurochem. 49:1987;138-145.
42. Chergui K., Charlety J., Akaoka H., Saunier C.F., Brunet J.-L., Buda M., Scensson T.H., Chouvet G. Tonic activation of NMDA receptors causes spontaneous burst discharge of rat midbrain dopamine neurons in vivo. Eur. J. Neurosci. 5:1993;137-144.
43. Chesselet M.F., Delfs J.M. Basal ganglia and movement disorders: an update. Trends Neurosci. 19:1996;417-422.
44. Chevalier G., Deniau J.M. Disinhibition as basic process in the expression of striatal functions. Trends Neurosci. 13:1990;277-280.
45. Christoffersen C.L., Meltzer L.T. Evidence for N-methyl-D-aspartate and AMPA subtypes of the glutamate receptor on substantia nigra dopamine neurons: possible preferential role for the N-methyl-D-aspartate receptors. Neuroscience. 67:1995;373-381.
46. Clarke N.P., Bolam J.P. Distribution of glutamate receptor subunits at neurochemically characterized synapses in the entopeduncular nucleus and subthalamic nucleus of the rat. J. Comp. Neurol. 397:1998;403-420.
47. Cleeter M.W., Cooper J.M., Schapira A.H. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J. Neurochem. 58:1992;786-789.
48. Cossette M., Levesque M., Parent A. Extrastriatal dopaminergic innervation of human basal ganglia. Neurosci. Res. 34:1999;51-54.
49. Coyle J.T., Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 262:1993;689-695.
50. 1 dopamine receptor in the rat brain: quantitative autoradiographic localization using an iodinated ligand. Neuroscience. 26:1988;83-100.
51. Delfs J.M., Ciaramitaro V.M., Parry T.J., Chesselet M.F. Subthalamic nucleus lesions: widespread effects on changes in gene expression induced by nigrostriatal dopamine depletion in rats. J. Neurosci. 15:1995;6562-6575.
52. DeLong M.R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 13:1990;281-285.
53. Deniau J.M., Menetrey A., Thierry A.M. Indirect nucleus accumbens input to the prefrontal cortex via the substantia nigra pars reticulata: a combined anatomical and electrophysiological study in the rat. Neuroscience. 61:1994;533-545.
54. Dexter D.T., Carter C.J., Wells F.R., Javoy-Agid F., Javoy-Agid Y., Less A., Jenner P. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52:1989;381-389.
55. Ebadi M., Srinivasan S.K., Baxi M.D. Oxidative stress and antioxidant therapy in Parkinson's disease. Progr. Neurobiol. 48:1996;1-19.
56. Ehringer, H., Hornykiewicz, O., 1960. Verteilung von noradrenalin und dopamin (3-hydroxytyramin) im gehirn des menschen und ihr verhalten bei erkrankungen des extrapyramidalen systems. Klinische Wochenschrift 1236-1239.
57. +, and adenosine triphosphate in isolated brain synaptosomes. J. Gen. Physiol. 95:1990;591-616.
58. Fèger J. Updating the functional model of the basal ganglia. Trends Neurosci. 20:1997;152-153.
59. Ferrè S., O'Connor W.T., Fuxe K., Ungerstedt U. The striatopallidal neuron - a main locus for adenosine-dopamine interactions in the brain. J. Neurosci. 13:1993;5402-5406.
60. 1 receptor-mediated mechanisms. Eur. J. Neurosci. 8:1996;1545-1553.
61. 1 receptor antagonist binding sites. Neurosci. Lett. 208:1996;109-112.
62. Flores G., Liang J.J., Sierra A., Martinez-Fong D., Quirion R., Aceves J., Srivastava L.K. Expression of dopamine receptors in the subthalamic nucleus of the rat: characterization using reverse transcriptase-polymerase chain reaction and autoradiography. Neuroscience. 91:1999;549-556.
63. Fonnum F., Gottesfeld Z., Grofova I. Distribution of glutamate decarboxylase, choline acetyltransferase and aromatic amino acid decarboxilase in the basal ganglia of normal and operated rats. Evidence for striatopallidal, striatoentopeduncular and striatonigral GABAergic fibres. Brain Res. 143:1978;125-138.
64. Fotuhi M., Sharp A.H., Glatt C.E., Hwang P.M., von Krosigk M., Snyder S.H., Dawson T.M. Differential localization of phosphoinositide-linked metabotropic glutamate receptor (mGluR1) and the inositol 1,4,5-trisphosphate receptor in rat brain. J. Neurosci. 13:1993;2001-2012.
65. Fujimoto K., Kita H. Response characteristic of subthalamic neurons to the stimulation of the sensorimotor cortex in the rat. Brain Res. 609:1993;185-192.
66. Gancher S., Mayer A. Sensitization to apomorphine-induced rotational behavior in 6-OHDA-lesioned rats: effects of NMDA antagonists on drug response. Brain Res. 68:1995;263-268.
67. Gasser T., Muller-Myhsok B., Wszolek Z.K., Durr A., Vaughan J.R., Bonifati V., Meco G., Bereznai B., Oehlmann R., Agid Y., Brice A., Wood N. Genetic complexity and Parkinson's disease. Science. 277:1997;388-389.
68. Gerfen C.F. The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci. 15:1992;133-139.
69. 1-containing neurons. J. Neurosci. 15:1995;8167-8176.
70. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14:1978;633-643.
71. Graybiel A.M. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci. 13:1990;244-254.
72. Greenamyre J.T., Porter R.H.P. Anatomy and physiology of glutamate in the CNS. Neurology. 44:(suppl.8):1994;S7-S13.
73. Greenamyre J.T., Higgins D.S., Eller R.V. Quantitative autoradiography of dihydrorotenone binding to complex I of the electron transport chain. J. Neurochem. 59:1992;747-749.
74. Greenamyre J.T., Eller R.V., Zhang Z., Ovadia A., Kurlan R., Gash D.M. Antiparkinsonian effects of remacemide, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann. Neurol. 35:1994;655-661.
75. Greene J.G., Greenamyre J.T. Bioenergetics and glutamate excitotoxicity. Prog. Neurobiol. 48:1996;613-634.
76. Greene J.G., Greenamyre J.T. Characterization of the excitotoxic potential of the reversible succinate dehydrogenase inhibitor malonate. J. Neurochem. 64:1995;430-436.
77. Grenhoff J., Johnson S.W. Electrophysiological effects of dopamine receptor stimulation. Neve K.A., Neve R.L. The Dopamine Receptors. 1997;267-304 Humana Press, Totowa, NJ.
78. Groenewegen H.J., Berendse H.W. Connections of the subthalamic nucleus with ventral striatopallidal parts of the basal ganglia in the rat. J. Comp. Neurol. 294:1990;607-622.
79. Groenewegen H.J., Berendse H.W., Haber S.N. Organization of the ventral striatopallidal system in the rat: ventral pallidal efferents. Neuroscience. 57:1993;113-142.
80. Halliday G., Harding A., Paxinos G. Serotonin and tachykinin system. Paxinos G. The Rat Nervous System. 1995;929-974 Academic Press, San Diego.
81. Hartley A., Stone J.M., Heron C., Cooper J.M., Schapira A.H. Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease. J. Neurochem. 994:(63):1994;1987-1990.
82. Hassani O.K., Feger J. Effects of intrasubthalamic injection of dopamine receptor agonists on subthalamic neurons in normal and 6-hydroxydopamine-lesioned rats: an electrophysiological and c-Fos study. Neuroscience. 92:1999;533-543.
83. Hassani O.K., Mouroux M., Feger J. Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus. Neuroscience. 72:1996;105-115.
84. Hassani O.K., Feger J., Yelnik J., Francois C. Evidence for a dopaminergic innervation of the subthalamic nucleus in the rat. Brain Res. 749:1997;88-94.
85. Hauber W. Involvement of basal ganglia transmitter systems in movement initiation. Progr. Neurobiol. 56:1998;507-540.
86. Hedreen J.C. Tyrosine hydroxylase-immunoreactive elements in the human globus pallidus and subthalamic nucleus. J. Comp. Neurol. 409:1999;400-410.
87. Heimer L., Zahm D.S., Aldheid G.F. Basal ganglia. Paxinos G. The Rat Nervous System. 1995;579-628 Academic Press, San Diego.
88. Hu X.-T., Wang R.Y. Comparison of effects of D-1 and D-2 dopamine receptor agonists on neurons in the rat caudate putamen. An electrophysiological study. J. Neurosci. 8:1988;4340-4348.
89. A receptor subunit mRNAs in monkey thalamus. J. Neurosci. 16:1996;3576-3589.
90. Jellinger K. The pathology of parkinsonism. Marsden C.D., Fahn S. Movement Disorders 2. 1987;124-165 Butterworths, London.
91. Johnson S.W., Hoffer B.J., Freedman R. Investigation of the failure of parenterally administered haloperidol to antagonize dopamine released from micropipettes in the caudate. J. Neurosci. 6:1986;572-580.
92. Johnson A.E., Coirini H., Källström L., Wiesel F.A. Characterization of dopamine receptor binding sites in the subthalamic nucleus. Neuroreport. 5:1994;1836-1838.
93. Jonsson G. Chemical neurotoxins as denervation tool in neurobiology. Annu. Rev. Neurosci. 3:1980;169-187.
94. Kaatz K.W., Albin R.L. Intrastriatal and intrasubthalamic stimulation of metabotropic glutamate receptors: a behavioral and fos immunoistochemical study. Neuroscience. 66:1995;55-65.
95. Kafetzopoulos E., Papadopoulos G. Turning behavior after unilateral lesion of the subthalamic nucleus in the rats. Behav. Brain Res. 8:1983;217-233.
96. Karcz-Kubicha M., Lorenz B., Danysz W. GlycineB antagonists and partial agonists in rodent models of Parkinson's disease - comparison with uncompetitive N-methyl-D-aspartate receptor antagonist. Neuropharmacology. 38:1999;109-119.
97. Kawaguchi Y., Wilson C.J., Augood S.J., Emson P.C. Striatal interneurones: chemical, physiological and morphological characterization. Trends Neurosci. 18:1995;527-535.
98. 14C ]-2-deoxyglucose autoradiographic study. J. Neurosci. 17:1997;4415-4425.
99. Kearney J.A., Becker J.B., Frey K.A., Albin R.L. The role of nigrostriatal dopamine in metabotropic glutamate agonist-induced rotation. Neuroscience. 87:1998;881-891.
100. Kelley A.E. The amygdalostriatal projection in the rat - an anatomical study by anterograde tracing methods. Neuroscience. 7:1982;615-630.
101. Kemp J.M., Powell T.P. The structure of the caudate nucleus of the cat: light and electron microscopy. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 262:1971;383-401.
102. Kita H., Kitai S.T. Efferent projections of the subthalamic nucleus in the rat: light and electron microscopic analysis with the PHA-L method. J. Comp. Neurol. 260:1987;435-452.
103. Kita H., Kitai S.T. Glutamate decarboxylase immunoreactive neurons in rat neostriatum: their morphological types and populations. Brain Res. 447:1988;346-352.
104. Kita H., Chang H.T., Kitai S.T. Pallidal inputs to subthalamus: intracellular analysis. Brain Res. 264:1983;255-265.
105. Kiyatkin E.A., Rebec G.V. Dopaminergic modulation of glutamate-induced excitation of neurons in the neostriatum and nucleus accumbens of awake, unrestrained rats. J. Neurophysiol. 75:1996;142-153.
106. 2 dopamine receptors in freely moving rats. J. Neurosci. 19:1999;3594-3609.
107. Klockgether T., Turski L. NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats. Ann. Neurol. 28:1990;536-539.
108. Klockgether T., Jacobsen P., Löschmann P.A., Turski L. The antiparkinsonian agent budipine is an N-methyl-D-aspartate antagonist. J. Neural Transm. [Park Dis - Dement Sect]. 5:1993;101-106.
109. 3H ]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur. J. Pharmacol. 166:1989;589-590.
110. Klockgether T., Turski L., Honor T., Zhang Z., Gash D.M., Kurlan R., Greenamyre J.T. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann. Neurol. 30:1991;717-723.
111. Kornhuber J., Bormann J., Hubers M., Rusche K., Riederer P. Effects of the 1-amino-adamantines at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur. J. Pharmacol. 206:1991;297-300.
112. Kosinski C.M., Standaert D.G., Counihan T.J., Scherzer C.R., Kerner J.A., Daggett L.P., Velicelebi G., Penney J.B., Young A.B., Landwehrmeyer G.B. Expression of N-methyl-D-aspartate receptor subunit mRNAs in the human brain: striatum and globus pallidus. J. Comp. Neurol. 390:1998;63-74.
113. Kosinski C.M., Standaert D.G., Testa C.M., Penney J.B., Young A.B. Expression of metabotropic glutamate receptor 1 isoforms in the substantia nigra pars compacta of the rat. Neuroscience. 86:1998;783-798.
114. 1 receptor agonists increase the firing rate of subthalamic nucleus neurons. Neuroscience. 72:1996;863-876.
115. Kreiss D.S., Mastropietro C.W., Rawji S.S., Walters J.R. The response of subthalamic nucleus neurons to dopamine receptor stimulation in a rodent model of Parkinson's disease. J. Neurosci. 17:1997;6807-6819.
116. Krige D., Carroll M.T., Cooper J.M., Marsden C.D., Schapira A.H.V. Platelet mitochondrial function in Parkinson's disease. Ann. Neurol. 32:1992;782-788.
117. Krüger R., Kuhn W., Müller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., Riess O. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nature Genet. 18:1998;106-108.
118. A receptor subunit messenger RNAs in the motor-related thalamic nuclei and basal ganglia of Macaca Mulatta studied with in situ hybridization histochemistry. Neuroscience. 85:1998;179-204.
119. Kure S., Tominaga T., Yoshimoto T., Tada K., Narisawa K. Glutamate triggers internucleosomal DNA cleavage in neuronal cells. Biochem. Biophys. Res. Commun. 179:1991;39-45.
120. Lai C.T., Yu P.H. Dopamine and L-Beta-3,4-dihydroxyphenylalanine hydrochloride (L-DOPA)-induced cytotoxicity towards catecholaminergic neuroblastoma. Biochem. Pharmacol. 53:1997;363-372.
121. Landwehrmeyer G.B., Standaert D.G., Testa C.M., Penney J.B., Young A.B. NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. J. Neurosci. 15:1995;5297-5307.
122. Lange K.W., Kornhuber J., Riederer P. Dopamine/glutamate interactions in Parkinson's disease. Neurosci. Biobehav. Rev. 21:1997;393-400.
123. Langston J.W., Ballard P.A., Tetrud J.W., Irwin I. Chronic parkinsonism in humans due to a product of meperidine analog synthesis. Science. 219:1983;979-980.
124. Lindvall O., Böjrklund A. Dopaminergic innervation of the globus pallidus by collaterals from the nigrostriatal pathway. Brain Res. 172:1979;169-173.
125. Löschmann P.A., Lange K.A., Kunow M., Rettig K.J., Jähnig P., Honoré T., Turski L., Wachtel H., Jenner P., Marsden C.D. Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-Dopa in models of Parkinson's disease. J. Neural. Transm. [Park Dis - Dement Sect]. 3:1991;203-213.
126. Markey S.P., Johannessen J.N., Chiueh C.C., Burns R.S., Herkenham M.A. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature. 311:1984;464-467.
127. 125I ]iodosulpiride, a highly selective ligand. Science. 228:1985;752-755.
128. Martignoni E., Blandini F., Godi L., Desideri S., Pacchetti C., Mancini F., Nappi G. Peripheral markers of oxidative stress in Parkinson's disease. The role of L-dopa. Free Rad. Biol. Med. 27:1999;428-437.
129. McBain C.J., Mayer L. N-Methyl-D-aspartic acid receptor structure and function. Physiol. Rev. 74:1994;723-760.
130. McGeorge A.J., Faull R.L.M. The organization of the projection from the cerebral cortex to the striatum in the rat. Neuorscience. 29:1989;503-537.
131. A-receptor subtypes really occur in the brain? Trends Neurosci. 19:1996;139-143.
132. Meldrum B., Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol. Sci. 11:1990;379-387.
133. Mercuri N., Bernardi G., Calabresi P., Cotugno A., Levi G., Stanzione P. Dopamine decreases cell excitability in rat striatal neurons by pre- and postsynaptic mechanisms. Brain Res. 358:1985;110-121.
134. Mitchell I.J., Clarke C.E., Boyce S., Robertson R.G., Peggs D., Sambrook M.A., Crossman A.R. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-1,2,3,6-tetrahydropyridine. Neuroscience. 32:1989;226-231.
135. Montastruc J.L., Rascol O., Senard J.M., Rascol A. A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 55:1992;630-631.
136. Montastruc J.L., Fabre N., Rascol O., Senard J.M., Blin O. N-Methyl-D-aspartate (NMDA) antagonists and Parkinson's disease: a pilot study with dextrometorphan. Mov. Disord. 9:1994;242-243.
137. Morelli M., Fenu S., Garau L., Di Chiara G. Time and dose dependence of the "priming" of the expression of dopamine receptor supersensitivity. Eur. J. Pharmacol. 162:1989;329-335.
138. 2-mediated behavior in the 6-hydroxydopamine model of turning: relationship with c-fos expression. J. Pharmacol. Exp. Ther. 260:1992;402-408.
139. 1 receptor stimulation in 6-OHDA lesioned rats: effect of sensitization (priming) with a dopaminergic agonist. Synapse. 13:1993;264-269.
140. Morelli M., Pinna A., Fenu S., Carta A., Cozzolino A., Di Chiara G. Differential effects of MK 801 and scopolamine on c-fos expression induced by L-dopa on the striatum of 6-hydroxydopamine lesioned rats. Synapse. 18:1994;288-293.
141. 2 receptors. J. Neural Trans. 100:1993;123-135.
142. 125I ]sulpiride binding in the subthalamic nucleus of rats with nigrostriatal lesions. Neuroreport. 14:1999;1501-1505.
143. Murphy T.H., Miyamoto M., Sastre A., Schnaar R.L., Coyle J.T. Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. Neuron. 2:1989;1547-1558.
144. Naito A., Kita H. The cortico-pallidal projection in the rat: an anterograde tracing study with biotinylated dextran amine. Brain Res. 653:1994;251-257.
145. Naito A., Kita H. The cortico-nigral projection in the rat: an anterograde tracing study with biotinylated dextran amine. Brain Res. 637:1994;317-322.
146. Nakao N., Ekini N., Nakai K., Itakura T. Ablation of the subthalamic nucleus supports the survival of nigral dopaminergic neurons after nigrostriatal lesions induced by the mitochondrial toxin 3-nitropropionic acid. Ann. Neurol. 45:1999;640-651.
147. Nauta H.J.W. Projections of the pallidal complex: an autoradiographic study in the cat. Neuroscience. 4:1979;1853-1873.
148. Nicklas W.J., Vyas I., Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyride, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropiridine. Life Sci. 36:1985;2503-2508.
149. Nicola S.M., Kombian S.B., Malenka R.C. Psychostimulants depress excitatory synaptic transmission in the nucleus accumbens via presynaptic D-1 like dopamine receptors. J. Neurosci. 16:1996;1591-1604.
150. Nicoletti F., Bruno V., Copani A., Casabona G., Knopfel T. Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Trends Neurosci. 19:1996;267-271.
151. Nieuwenhuys R. Chemoarchitecture of the Brain. 1990;Kluwer Academic Publishers, Dordrecht.
152. Novelli A., Reilly J.A., Lysko P.G., Henneberry R.C. Glutamate becomes neurotoxic via the NMDA receptor when intracellular energy levels are reduced. Brain Res. 451:1988;205-212.
153. O'Donnell P., Grace A.A. Dopaminergic reduction of excitability in nucleus accumbens neurons recorded in vitro. Neuropsychopharmacology. 15:1996;87-97.
154. Oertel W.H., Mugnaini E. Immunocytochemical studies of GABAergic neurons in rat basal ganglia and their relations to other neuronal systems. Neurosci. Lett. 47:1984;233-238.
155. Ohishi H., Shigemoto R., Nakanishi S., Mizuno N. Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat. Neuroscience. 53:1993;1009-1018.
156. Ohno Y., Sasa M., Takaori S. Coexistence of inhibitory dopamine D-1 and excitatory D-2 receptors on the same caudate nucleus neurons. Life Sci. 40:1987;1937-1945.
157. Olanow C.W. A rationale for dopamine agonists as primary therapy for Parkinson's disease. Can. J. Neurol. Sci. 19:1992;108-112.
158. Olanow C.W., Jenner P., Brooks D. Dopamine agonists and neuroprotection in Parkinson's disease. Ann. Neurol. 44:(suppl 1):1998;S167-S174.
159. Olney J.W., Ho O.L., Rhee V. Cytotoxic effects of acidic amino acids on the infant mouse central nervous sytem. Exp. Brain. Res. 14:1971;61-76.
160. Papa S.M., Chase T.N. Levodopa-induced dyskenesias improved by a glutamate antagonist in parkinsonian monkeys. Ann. Neurol. 39:1996;574-578.
161. Pardo B., Mena M.A., Casarejos M.J., Paino C.L., De Yebenes J.G. Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants. Brain Res. 682:1995;133-143.
162. Parent A., Cicchetti F. The current model of basal ganglia organization under scrutiny. Mov. Disord. 13:1998;199-202.
163. Parent A., Hazrati L.N. Functional anatomy of the basal ganglia. Part I: The cortico-basal ganglia-thalamo-cortical loop. Brain Res. Rev. 20:1995;91-127.
164. Parent A., Hazrati L.N. Functional anatomy of the basal ganglia. Part II: The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Res. Rev. 20:1995;128-154.
165. Parker W.D., Boyson S.J., Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26:1989;719-723.
166. 1 dopamine receptor behavioral response is dissociated from striatal immediate-early gene activity. Neuroscience. 66:1995;347-359.
167. Perry T.L., Yong V.W. Idiopathic Parkinson's disease, progressive sopranuclear palsy and glutathion metabolism in the substantia nigra of patients. Neurosci. Lett. 67:1986;269-274.
168. Piallat B., Benazzouz A., Benabid A.L. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after strital 6-OHDA injection: behavoral and immunohistochemical studies. Eur. J. Neurosci. 8:1996;1408-1414.
169. Poirier J., Dea D., Baccichet A., Thiffault C. Superoxide dismutase expression in Parkinson's disease. Ann. N.Y. Acad. Sci. 738:1994;116-120.
170. Pollak P., Benabid A.L., Limousin P., Benazzouz A. Chronic intracerebral stimulation in Parkinson's disease. Adv. Neurol. 345:1997;213-220.
171. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 276:1997;2045-2047.
172. Porter R.H.P., Greenamyre J.T. Variations in the regional pharmacology of NMDA receptor channel blockers: implications for therapeutic potential. J. Neurochem. 64:1995;614-623.
173. Porter R.H.P., Greene J.G., Higgins D.S., Greenamyre J.T. Polysynaptic regulation of glutamate receptors and mitochondrial enzyme activities in the basal ganglia of rats with unilateral dopamine depletion. J. Neurosci. 14:1994;7192-7199.
174. Reese N.B., Garcia-Rill E., Skinner R.D. The pedunculopontine nucleus. Auditory input, arousal and pathophisiology. Progr. Neurobiol. 42:1995;105-133.
175. Reiner A., Medina L., Haber S.N. The distribution of dynorphinergic terminals in striatal target regions in comparison to the distribution of substance P-containing and enkephalinergic terminals in monkeys and humans. Neuroscience. 88:1999;775-793.
176. Ribak C.E., Vaughn J.E., Roberts E. GABAergic nerve terminals decrease in the substantia nigra following hemitransection of the striatonigral and pallidonigral pathways. Brain Res. 192:1980;413-420.
177. Richfield E.K., Young A.B., Penney J.B. Comparative distribution of dopamine D-1 and D-2 receptors in the basal ganglia of turtles, pigeons, rats, cats, and monkeys. J. Comp. Neurol. 262:1987;446-463.
178. Rodriguez M., Gonzalez-Hernandez T. Electrophysiological and morphological evidence for a GABAergic nigrostriatal pathway. J. Neurosci. 19:1999;4682-4694.
179. Rodriguez M.C., Obeso A., Olanow W. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann. Neurol. 44:(suppl 1):1998;S175-S188.
180. 1 receptor modulation of glutamate receptor messenger RNA levels in the neocortex and neostriatum of unilaterally 6-hydroxydopamine-lesioned rats. Neuroscience. 89:1999;781-797.
181. Rolls E.T., Thorpe S.J., Boytim M., Szabo I., Perrett D.I. Responses of striatal neurons in the behaving monkey. Part 3: Effects of iontophoretically applied dopamine on normal responsiveness. Neuroscience. 12:1984;1201-1212.
182. Romano C., Sesma M.A., McDonald C.T., O'Malley K., Van den Pol A.N., Olney J.W. Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J. Comp. Neurol. 8:1995;455-469.
183. Rothman S.M., Olney J.W. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann. Neurol. 19:1986;105-111.
184. 1 dopamine receptors influence Fos immunoreactivity in the globus pallidus and subthalamic nucleus of intact and nigrostriatal-lesioned rats. Brain Res. 703:1995;156-164.
185. Saji M., Blau A.D., Volpe B.T. Prevention of transneuronal degeneration of neurons in the substantia nigra reticulata by ablation of the subthalamic nucleus. Exp. Neurol. 141:1996;120-129.
186. Sanchez-Ramos J., Overvik E., Ames B.N. A marker of oxyradical-mediated DNA damage (8-hydroxy-2′-deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration. 3:1994;197-204.
187. Sauer H., Oertel W.H. Progressive degeneration of dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience. 59:1994;401-415.
188. Schapira A.H.V., Cooper J.M., Dexter D., Clark J.B., Jenner P., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54:1990;823-827.
189. Schiffman S.N., Jacobs O., Vanderhaeghen J.J. The striatal restricted adenosine A2 receptors is expressed by enkephalin but not by substance P neurons: an in-situ hybridization histochemistry study. J. Neurochem. 57:1991;1062-1067.
190. Scorrano L., Petronilli V., Bernardi P. On the voltage dependence of the mitochondrial permeability transition pore a critical appraisal. J. Biol. Chem. 272:1997;12295-12299.
191. Sellal F., Hirsh E., Lisovoski F., Mutshler V., Collard M., Marescaux C. Contralateral disappearance of parkinsonian signs after subthalamotomic hematoma. Neurology. 42:1992;255-256.
192. Shinotoh H., Vingerhoets F.J.G., Lee C.S., Uitti R.J., Schulzer M., Calne D.B., Tsui J. Lamotrigine trial in idiopathic parkinsonism: a double-blind, placebo-controlled, crossover study. Neurology. 48:1997;1282-1285.
193. Shults C.W., Nasirian F., Ward D.M., Nakano K., Pay M., Hill L.R., Haas R.H. Carbidopa/levodopa and selegiline do not affect platelet mitochondrial function in early parkinsonism. Neurology. 45:1995;344-348.
194. Sian J., Fexter D.T., Lees A.J., Daniel S., Jenner P., Marsden C.D. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 36:1994;348-355.
195. Smith Y., Bevan M.D., Shink E., Bolam J.P. Microcircuitry of the direct and indirect pathways of the basal ganglia. Neuroscience. 86:1998;353-387.
196. Smith I.D., Grace A.A. Role of the subthalamic nucleus in the regulation of nigral dopamine neuron activity. Synapse. 12:1992;287-303.
197. Smith Y., Bolam J.P. Neurons of the substantia nigra reticulata receive a dense GABA-containing input from the globus pallidus in the rat. Brain Res. 493:1989;160-167.
198. Smith Y., Parent A. Neurons of the subthalamic nucleus in primates display glutamate but not GABA immunoreactivity. Brain Res. 453:1988;353-356.
199. Smith Y., Charara A., Parent A. Synaptic innervation of mid-brain dopaminergic neurons by glutamate-enriched terminals in the squirrel monkey. J. Comp. Neurol. 364:1996;231-253.
200. Surmeier D.J., Song W.-J., Yan Z. Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J. Neurosci. 16:1996;6579-6591.
201. Tallaksen-Greene S.J., Albin R.L. Localization of AMPA-selective excitatory amino acid receptor subunits in identified populations of striatal neurons. Neuroscience. 61:1994;509-519.
202. Tallaksen-Greene S.J., Wiley R.G., Albin R.L. Localization of striatal excitatory amino acid binding site subtypes to striatonigral projection neurons. Brain Res. 594:1992;165-170.
203. Tan S., Wood M., Maher P. Oxidative stress induces a form of programmed cell death with characteristics of both apoptosis and necrosis in neuronal cells. J. Neurochem. 71:1998;95-105.
204. Tatton N.A., Kish S.J. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropiridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience. 77:1997;1037-1048.
205. Tatton W.G., Chalmers-Redman R.M.E. Mitochondria in neurodegenerative apoptosis: an opportunity for therapy? Ann. Neurol. 44:(1):1998;S134-S141.
206. Tatton W.G., Chalmers-Redman R.M.E., Ju W.Y.H., Wadia J., Tatton N.A. Apoptosis in neurodegenerative disorders: potential for therapy by modifying gene transcription. J. Neural. Transm. 49:1997;245-268.
207. A receptor-mediated inhibition of rat substantia nigra dopaminergic neurons by pars reticulata projection neurons. J. Neurosci. 15:1995;3092-3103.
208. Testa C.M., Standaert D.G., Young A.B., Penney J.B. Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat. J. Neurosci. 14:1994;3005-3018.
209. + neurotoxicity by N-methyl-D-aspartate antagonists. Nature. 349:1991;414-418.
210. Tzagournissakis M., Dermon C.R., Savaki H.E. Functional metabolic mapping of the rat brain during unilateral electrical stimulation of the subthalamic nucleus. J. Cereb. Blood Flow Metab. 14:1994;132-144.
211. Ungerstedt U. 6-hydroxydopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol. 5:1968;107-110.
212. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. (suppl.). 367:1971;69-93.
213. Ungerstedt U., Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res. 24:1970;485-493.
214. Verhagen Metman L., Del Dotto P., van den Munckhof P., Fang J., Mouradian M.M., Chase T.N. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology. 50:1998;1323-1326.
215. Vila M., Levy R., Herrero M.T., Faucheux B., Obeso J.A., Agid Y., Hirsch E.C. Metabolic activity of the basal ganglia in parkinsonian syndromes in human and non-human primates: a cytochrome oxidase histochemistry study. Neuroscience. 71:1996;903-912.
216. Vila M., Marin C., Ruberg M., Jimenez A., Raisman-Vozari R., Agid Y., Tolosa E., Hirsch E.C. Systemic administration of NMDA and AMPA receptor antagonists reverses the neurochemical changes induced by nigrostriatal denervation in basal ganglia. J. Neurochem. 73:1999;344-352.
217. Ward R.P., Dorsa D.M. Colocalization of the serotonin receptor subtypes 5-HT2A, 5-HT2C, and 5-HT6 with neuropeptides in rat striatum. J. Comp. Neurol. 370:1996;405-415.
218. A receptor subunit mRNAs in the rat brain. Part I: Telencephalon, Diencephalon, Mesencephalon. J. Neurosci. 12:1992;1040-1062.
219. Wong-Riley M.T.T. Cytochrome oxidase: an endogenous metabolic marker for neuronal activity. Trends Neurosci. 12:1989;94-101.
220. Wright D.E., Seroogy K.B., Lundgren K.H., Davis B.M., Jennes L. Comparative localization of serotonin 1A, 1C, and 2 receptor subtype mRNAs in rat brain. J. Comp. Neurol. 351:1995;357-373.
221. Wüllner U., Testa C.M., Catania M.V., Young A.B., Penney J.B. Glutamate receptors in the striatum and substantia nigra: effects of medial forebrain bundle lesions. Brain Res. 645:1994;98-102.
222. Yamamoto B.K., Cooperman M.A. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J. Neurosci. 14:1994;4159-4166.
223. Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E.R., Mizuno Y. Immunoistochemical detection of 4-hydroxynonenal protein adducts in Parkinson's disease. Proc. Nat. Acad. Sci. 93:1996;2696-2713.
224. Yoshino H., Nakagawa-Hattori Y., Kondo T., Mizuno Y. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease. J. Neural Transm. (Park. Dis. - Dement Sect). 4:1992;27-34.
225. 2 dopamine receptors in the basal ganglia of the rat: light and electron microscopy. Neuroscience. 65:1995;709-730.
226. Yung K.K.L., Smith A.D., Levey A.I., Bolam J.P. Synaptic connections between spiny neurons of the direct and indirect pathways in the neostriatum of the rat: evidence from dopamine receptor and neuropeptide immunostaining. Eur. J. Neurosci. 8:1996;861-869.
227. Zhang J., Price J.O., Graham D.G., Montine T.J. Secondary excitotoxicity contributes to dopamine-induced apoptosis of dopaminergic neuronal cultures. Biochem. Biophys. Res. Comm. 248:1998;812-816.
228. Zigmond M.J., Abercrombie E.D., Berger T.W., Grace A.A., Stricker E.M. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 13:1990;290-296.
229. Zipp F., Burklin F., Fischer P.A. Lamotrigine: antiparkinsonian activity by blockade of glutamate release? J. Neural Transm. [Park Dis - Dement Sect]. 10:1995;199-206.
230. Ziv I., Zilkha-Falb R., Offen D., Shirvan A., Barzilai A., Melamed E. Levodopa induced apoptosis in cultured neuronal cells - a possible accelerator of nigrostriatal degeneration in Parkinson's disease? Mov. Disord. 1:1997;17-23.